Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Combatting Antimicrobi...

By João L. Carapinha

December 12, 2025

Provisional Deal Ushers in EU Pharmaceutical Reform The European Parliament and Council have reached a provisional agreement to overhaul the EU's pharmaceutical policy framework, marking a major step in the EU Pharmaceutical Refor...
AI Governance Pharmaceuticals: Ensuring Ethical AI Integration in the Medicines Lifecycle

By HEOR Staff Writer

December 9, 2025

In the pharmaceutical industry, AI governance in pharmaceuticals is crucial for harnessing artificial intelligence's potential in drug discovery, clinical trials, and patient monitoring. How can pharma companies integrate AI ethically across the medicines lifecycle? This article draws on a recent...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions
Expansion of Coverage in the 2025 National Basic Medical Insurance Drug Catalog In this update we highlight updates and implications of the 2025 National Basic Medical Insurance Drug Catalog in China's ...